Morgan Stanley starts Certara at 'equal weight'

Certara

03/07/2025 12:53

** Morgan Stanley initiates coverage of drug development software provider Certara CERT.O with an "equal weight" rating

** "A key focus for the company is biosimulation, where Certara's platforms are designed to optimize drug design and testing" - Brokerage

** Morgan Stanley says CERT has a market-leading platform and generates strong recurring revenues with significant cross-selling opportunities

** Brokerage PT remains unchanged at $16, a ~39.3% upside on the stock's last close

** Five of 11 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $16 - LSEG data

** As of last close, stock up ~7.9% YTD

 (Reporting by Prakhar Srivastava in Bengaluru)

 ((Prakhar.srivastava2@thomsonreuters.com))